Bavarian Nordic: all 58 studies

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young AdultsNot yet recruitingNCT07888088Phase 1
• An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and AdultsRecruitingNCT07467707Phase 3
• Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 YearsCompletedNCT05349617Phase 3Results posted
• ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2CompletedNCT05329220Phase 3Results posted
• MVA-BN-RSV Vaccine TrialTerminatedNCT05238025Phase 3Results posted
• ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult SubjectsCompletedNCT05077267Phase 2Results posted
• A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)CompletedNCT05072080Phase 3Results posted
• A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle VaccineCompletedNCT05065983Phase 2Results posted
• Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)CompletedNCT03992872Phase 2Results posted
• Freeze-Dried MVA-BN® Lot Consistency Smallpox TrialCompletedNCT03699124Phase 3Results posted
• CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03628716Phase 2Results posted
• BN Brachyury and Radiation in ChordomaCompletedNCT03595228Phase 2Results posted
• Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy AdultsCompletedNCT03483961Phase 2Results posted
• Special Access Program IMVAMUNE®CompletedNCT03472014Phase 4Results posted
• VAXCHORA Pediatric Study to Assess Safety and ImmunogenicityCompletedNCT03220737Phase 4Results posted
• RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old AdultsCompletedNCT02873286Phase 2Results posted
• A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older AdultsCompletedNCT02100631Phase 3Results posted
• A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy AdultsCompletedNCT02094586Phase 3Results posted
• Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedNCT02038881Phase 2Results posted
• A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®CompletedNCT01913353Phase 3Results posted
• Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent CholeraCompletedNCT01895855Phase 3Results posted
• A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsCompletedNCT01668537Phase 2Results posted
• A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerCompletedNCT01322490Phase 3Results posted
• A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 3Results posted
• A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 2Results posted
• An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedNCT00686582Phase 2Results posted
• A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisCompletedNCT00316602Phase 2Results posted
• Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsCompletedNCT00316589Phase 2Results posted
• A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedNCT00316524Phase 2Results posted
• Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingNCT07199569Phase 2
• A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Active, not recruitingNCT07003984Phase 3
• A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineActive, not recruitingNCT06899802Phase 2
• Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsActive, not recruitingNCT06549530Phase 2
• Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster VaccinationActive, not recruitingNCT06007183Phase 3
• Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy AdultsCompletedNCT04752644Phase 2
• TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing CancerCompletedNCT04246671Phase 1
• A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced CancerCompletedNCT04134312Phase 1
• Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult SubjectsCompletedNCT04131595Phase 1
• Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)CompletedNCT03349983Phase 1
• RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.WithdrawnNCT02864628Phase 1
• A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung CancerCompletedNCT02840994Phase 1
• Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV VaccineCompletedNCT02419391Phase 1
• Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among TravelersCompletedNCT02391909
• Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200CompletedNCT01585181Phase 1
• A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant TherapyCompletedNCT01152398Phase 1
• Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 YearsCompletedNCT00891007Phase 2
• A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate CancerCompletedNCT00629057Phase 1
• Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected SubjectsCompletedNCT00623259Phase 1
• A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast CancerCompletedNCT00485277Phase 1
• Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV InfectionCompletedNCT00390078Phase 1/2
• Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV InfectionCompletedNCT00386633Phase 1
• Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive SubjectsCompletedNCT00189969Phase 1
• Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedNCT00189956Phase 2
• Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy SubjectsCompletedNCT00189943Phase 1
• An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected PatientsCompletedNCT00189930Phase 2
• Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedNCT00189917Phase 1
• Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected PatientsCompletedNCT00189904Phase 1/2
• PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyCompletedNCT00078585Phase 2

← Bavarian Nordic overview and focus areas